Why Healthcare Needs Builders, Not Just Backers

A well-funded digital health startup has raised $15 million. The founding team is strong: a Stanford PhD, a YC alum, and a product veteran from a consumer app. They have built a beautiful clinical decision support tool. It works in beta. Nothing happens next.

The problem is not the product. The problem is that none of them has been inside an NHS procurement meeting, shepherded a submission through NICE, or managed the 18-month implementation cycle of a hospital technology deployment. They have built something that hospital procurement departments will evaluate using criteria they do not understand. They have not priced for a buyer who evaluates based on Total Cost of Ownership, not feature set. They have not learned that “we’ll iterate based on feedback” is disqualifying language in regulated healthcare.

This is the tourist founder problem in healthcare. Capital is abundant. Domain builders are not.

‍

The Failure Archetype

Healthcare and biotech lead in failure count with 62 companies and $5.1 billion in destroyed capital among VC-backed companies that shut down since 2023. More pointedly, healthcare startups face an 80% failure rate, substantially higher than technology startups generally.

The canonical explanation—“ran out of capital”—ranks first among failure reasons. But the deeper causes are poor product-market fit at 43%, bad timing at 29%, and unsustainable unit economics at 19%. These are not funding failures. These are execution failures rooted in misunderstanding the market.

For health tech, the misunderstanding is structural. A team building a SaaS tool for restaurants operates in a market where procurement is delegated to cost-conscious managers, implementation is measured in weeks, and failure doesn’t kill anyone. Healthcare procurement is the inverse on every axis: decisions are made by committees with conflicting incentives (clinician buy-in vs. budget officers vs. compliance), implementation scales from months to years, and failure is measured in patient safety.

‍

The Domain Expertise Advantage

Research on healthcare startup success reveals a consistent pattern: domain depth accelerates the learning curve, enabling faster problem definition, solution ranking, and iteration cadence. A founder who has managed hospital procurement understands why “integration with your EHR” is not a feature—it is the entire product from the buyer’s perspective. A founder who has worked as a clinical ops director knows that the tool will be evaluated not on accuracy but on whether it requires retraining 400 nurses.

The data is not simple. Some analyses show that founder healthcare expertise is less predictive of fundraising or exit outcomes than assumed, suggesting that domain knowledge alone is insufficient. But the nuance matters: deep domain knowledge is expected by most VCs for highly regulated life science or reimbursement-dependent models, and the most resilient healthcare ventures typically include a healthcare insider who understands clinical workflows, a technology architect who can design the platform, and a business operator who can scale operations.

The crucial insight: domain expertise is not a founder trait. It is a team architecture requirement.

‍

Venture Capital vs. Venture Building

Venture capital writes cheques and sits on boards. Venture building builds. The difference is material in healthcare.

IDEO’s health venture studio work and platforms like INITIATE, which co-creates companies at the intersection of healthcare and technology, operate on a different thesis: the value is not in spotting a promising entrepreneur and funding her. The value is in assembling a team with embedded domain expertise, providing patient capital that accepts 18-month implementation cycles, and treating regulatory and procurement complexity not as obstacles but as moats.

This requires different incentives. A VC fund measured on capital deployed and exits needs return velocity. A venture studio can afford to spend 18 months getting a technology integrated into three NHS Trusts before raising growth capital, because the burn is offset against the studio’s portfolio returns, not an individual fund’s IRR targets.

The result: venture studios in healthcare produce ventures that understand their market. They fail for different reasons—the technology was wrong, the timing was wrong—but not because the team didn’t understand who they were selling to.

‍

The Capital Opportunity

This does not mean venture capital should exit healthcare. It means venture capital applied to healthcare should be more disciplined about team composition. Before writing a cheque, ask: does this team have someone who has implemented hospital technology at scale? Does it have someone who understands NHS procurement? Does it have someone who has managed clinical validation?

If the answer is no, the company is not unfundable. But it requires a different kind of backing. It requires co-founders or advisors who embed domain knowledge into the product development process from month one. It requires patient capital willing to accept that healthcare timelines are different.

The venture studios that are succeeding in healthcare are not outrunning the VC funds. They are simply solving a problem VCs cannot: they are providing the operational infrastructure to translate a good idea into a regulatory-compliant, procurement-ready technology that hospitals can actually deploy.

The future of health tech venture building belongs to the founders who respect that healthcare is harder than it looks, who treat procurement cycles and regulatory pathways as product requirements, not bureaucracy to be circumvented, and who build teams that combine brilliant technology with hardened operational experience. The capital will follow once that discipline is visible.